卵巢子宫内膜样癌HER－2／neu的表达

目的研究卵巢子宫内膜样癌ＨＥＲ－２／ｎｅｕ的表达以及与临床病理特征和预后的关系。方法应用ＨＥＲ－２／ｎｅｕ单克隆抗体免疫组化技术对卵巢子宫内膜样癌２８例进行ＨＥＲ－２／ｎｅｕ癌基因蛋白测定。结果１３例细胞浆染色阳性，占４６．４％，Ⅰ期肿瘤阳性率为２０．０％，Ⅱ～Ⅳ期肿瘤阳性率为５２．２％，手术有残留肿瘤者ＨＥＲ－２／ｎｅｕ的表达率是６２．５％，无残留肿瘤者ＨＥＲ－２／ｎｅｕ表达率是２５．０％，差异有显著性（Ｐ＝０．０４９）。ＨＥＲ－２／ｎｅｕ表达与发病年龄、ＣＡ１２５水平、组织学分级及淋巴转移无关。术后随诊６～９６个月，平均３１．３个月，ＨＥＲ－２／ｎｅｕ阳性者术后死亡率是３８．５％，ＨＥＲ－２／ｎｅｕ阴性者术后死亡率是２１．４％。结论ＨＥＲ－２／ｎｅｕ阳性者与卵巢子宫内膜样癌的不良预后有一定的关系。     

子宫内膜癌ras及HER—2／neu癌基因的表达

子宫内膜癌ｒａｓ及ＨＥＲ－２／ｎｅｕ癌基因的表达薛凤霞焦书竹王海燕陈斌其为探讨ｒａｓ、ＨＥＲ－２／ｎｅｕ癌基因与子宫内膜癌临床及病理学特征的关系，本研究检测了１０３例子宫内膜癌组织中ｒａｓ、ＨＥＲ－２／ｎｅｕ癌基因的表达情况。一、材料和方法：１．临床...     

卵巢子宫内膜样癌p53抑癌基因蛋白的表达

卵巢子宫内膜样癌ｐ５３抑癌基因蛋白的表达冷金花，郎景和，郭丽娜，沈铿，许秀英本研究通过检测２８例卵巢子宫内膜样癌ｐ５３抑癌基因的表达情况，以探讨ｐ５３与卵巢子宫内膜样癌临床和病理表现的关系以及对预后的影响。一、材料和方法１．临床资料及组织标本：我院１...     

HER2／neu蛋白过度表达与卵巢癌研究进展

HER2／neu蛋白是原癌基因HER2／neu编码的一种具有酪氨酸激酶活性的跨膜糖蛋白，在卵巢癌的发生、转移及恶性表型维持中起着重要作用。约15％-30％的卵巢癌存在HER2/neu蛋白过度表达。HER2／neu蛋白过度表达与卵巢癌患者较短存活期相关，可作为预后因素。HER2/neu蛋白表达高低与卵巢癌对化疗药物敏感性有关，对临床化疗药物的选择起指导作用。但以HER2／neu蛋白为靶点的抗卵巢癌治疗效果需进一步临床实验验证。     

卵巢子宫内膜样癌同步子宫内膜病变的临床分析

目的:探讨卵巢子宫内膜样癌（OEC）同步子宫内膜病变的临床特点、治疗及预后。方法:收集1998年8月至2017年12月在北京大学人民医院接受治疗并经病理检查确诊为OEC的56例患者的临床病理资料,其中OEC同步子宫内膜病变患者13例（OEC同步内膜病变组）及单纯OEC患者43例（单一OEC组）。比较两组患者的临床特点、...     

卵巢子宫内膜样癌及其合并子宫内膜异位症的临床及病理分析

目的探讨卵巢子宫内膜样癌及其合并子宫内膜异位症患者的临床、病理特征及预后。方法对中国医科大学第二临床学院和解放军202医院1990年1月至2004年12月40例卵巢子宫内膜样癌患者病理蜡块进行分析,16例为子宫内膜异位症恶变（EM组）,24例为原发卵巢子宫内膜样癌（NEM组）,同期50例原发卵巢浆液性囊腺癌为对照组。比较分析3组一般特征、临床表现、病理特点及预后。结果EM组较NEM组年轻9岁,较对照组年轻5岁,临床主要表现为盆腔包块及下腹胀痛,盆腔包块持续半年以上患者多见。NEM组主要为下腹胀痛及阴道不规则流血。EM组5年存活率为75.0%,NEM组为62.5%。结论子宫内膜异位症恶变患者发病年龄较轻,临床医生要认识子宫内膜异位症恶变为卵巢子宫内膜样癌的临床及病理特点,提高早期诊断率。     

子宫内膜腺癌neu基因产物的测定

子宫内膜腺癌ｎｅｕ基因产物的测定徐燕杰，王一平，王政民应用ＡＢＣ免疫组织化学方法，对３５例子宫内膜腺癌的ｎｅｕ基因产物进行测定，探讨其临床意义。一、材料与方法１．标本来源：选取１９９０年２月至１９９４年２月我院及协作单位手术切除子宫内膜腺癌病例共３５...     

子宫内膜异位症与卵巢上皮性癌的关系

目的 探讨子宫内膜异位症（异位症）与卵巢（卵巢癌）的关系。方法 对３７１例卵巢癌中的２０例合并异位症的病列进行了回顾性分析,并与３５１例未合并异位症的病例（其中内膜样癌３８例,透明细胞癌３９例）进行对照研究。结果 ２０例合并异位症者中,内膜样癌１１例,透明细胞癌７例,腺癌和浆液睡性乳头腺癌各１例。合并异位症的卵巢癌与未合并异位症的同型卵巢癌相比较,前者细胞分化较好;应用Ｋａｐｌａｎ－Ｍｅｉｅｒ法计     

卵巢内膜样癌87例临床病理分析

1972年1月至1984年12月共收治卵巢内膜样癌87例，占卵巢上皮性恶性肿瘤的23．5％，卵巢内膜样癌的组织发生，可来自卵巢内的异位内膜恶变，谱可直接来自卵巢表面生发上皮的化生，按组织学将其分成四型，卵巢内膜样腺癌，卵巢透明细胞癌，卵巢鳞腺癌，卵巢角化腺部，各型的5年生存率分别为51．2，0，0及100．0％，卵巢内膜样癌的临床分期对预后很重要，本组5年及10年生存率为43．2％及43．2％，而临床四期分别为90．1％及90．1％，23．3及23．3％，4．6及0％，0％，治疗除以手术为为主的综合治疗外，术后可较长期应用激素类药物，以提高生存率减少复发率。     

Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma

AIM: To investigate the effect of HER-2/neu protein overexpression on chemoresistance and prognosis in patients with epithelial ovarian carcinoma. METHODS: A total of 141 ovarian carcinoma tissues surgically resected between 1987 and 2003 were assessed by immunohistochemistry (IHC). The characteristic of the patients and immunohistochemical results were compared by chi2-test. Survival analysis was performed by the Kaplan-Meier method and the log-rank test. RESULTS: HER-2/neu overexpression was detected in 18 cases (12.8%). There were no significant differences in histopathological subtypes (P = 0.3550), FIGO stages (P = 0.8858), or residual tumor size at first surgery (P = 0.6607) between the cases with HER-2/neu overexpression and the cases without HER-2/neu overexpression. Among the 58 cases which responded to chemotherapy, only five cases (8.6%) showed HER-2/neu overexpression. However, among the 38 cases which did not respond to chemotherapy, eight cases (21.1%) showed HER-2/neu overexpression. Overexpression of HER-2/neu had a tendency to relate with chemoresistance of epithelial ovarian carcinoma, but there were no statistically significant differences (P = 0.0817). No association was observed between HER-2/neu overexpression and cumulative survival rate (P = 0.4970). CONCLUSIONS: The results of the current study show that although HER-2/neu overexpression has a tendency to be associated with chemoresistance, it can not be a prognostic factor for the patients with epithelial ovarian carcinoma.     

Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma

OBJECTIVE: To evaluate the significance of the expression of HER-2/neu as a prognostic factor, we retrospectively examined its overexpression rates chiefly in ovarian clear cell adenocarcinoma (CCA) and their relationships with FIGO stage, lymph node metastasis, and prognosis. METHODS: In addition to 90 specimens of CCA (stage I, 52; stage II, 7; stage III, 28; stage IV, 3) obtained between 1987 and 2002, 19 specimens of serous adenocarcinoma (S), 19 specimens of mucinous adenocarcinoma (M), and 19 specimens of endometrioid adenocarcinoma (E) collected at initial surgery were studied. The expression of HER-2/neu was immunohistologically scored on a scale of 0 to 3+ according to the HercepTest scoring system, and 2+ and 3+ were regarded as overexpression. The relationship between HER-2/neu overexpression and outcome was evaluated by the Kaplan-Meier method and the log-rank test. The relationship with advanced-stage cancer was analyzed by Fisher's exact test. The relationships with lymph node metastasis and histologic types were compared by the t test. RESULTS: The rate of HER-2/neu overexpression in CCA was 45.6% (0, 1+, 2+, and 3+ in 14, 35, 36, and 5 cases, respectively), and no differences in the overexpression rate were noted among histologic types: 52.7% in S, 42.1% in M, and 26.4% in E. In CCA, no association was observed between HER-2/neu overexpression and cumulative survival rate (P = 0.5708), FIGO stage (P = 0.5147), or lymph node metastasis (P = 0.3624). CONCLUSION: The absence in CCA of an association between HER-2/neu overexpression and outcome, stage, or lymph node metastasis indicates that HER-2/neu overexpression is not a prognostic risk factor.     

卡培他滨对高表达HER-2/neu卵巢癌裸鼠的治疗作用

目的:探讨卡培他滨对高表达HER-2/neu卵巢癌裸鼠的治疗作用。方法:66只雌性健康裸鼠皮下接种人卵巢癌SKOV3细胞,建立试验模型。根据用药情况将裸鼠分成两组:对照组(塞来昔布灌胃治疗,33只)和观察组(塞来昔布联合卡培他滨灌胃治疗,33只)。比较两组SKOV3细胞的生长抑制率、肿瘤体积及肿瘤抑制率,同时观察两组裸鼠的p53标记指数、HER-2/neu标记指数。结果:观察组的细胞生长抑制率为(65.11±0.86)%,高于对照组(40.38±0.58)%,差异有统计学意义(P0.01)。观察组的肿瘤抑制率高于对照组,差异有统计学意义(P0.01)。观察组裸鼠的p53标记指数、HER-2/neu标记指数均低于对照组,差异有统计学意义(P0.01)。结论:卡培他滨在高表达HER-2/neu卵巢癌裸鼠的治疗中作用显著,能有效抑制肿瘤细胞的生长,作用机制可能是卡培他滨能调控p53、HER-2/neu基因表达。     

Expression of HER-2/neu oncoprotein, DNA-ploidy and S-phase fraction in advanced ovarian cancer

The immunohistochemical expression of HER-2/neu and cytofluorimetric data were retrospectively analyzed in a group of primary advanced ovarian cancers. Thirty-three out of 94 (35%) cases showed a specific p185/neu immunoreaction. No correlation between p185/neu expression and any of the clinico-pathologic parameters examined was observed. As far as cytofluorimetric data are concerned, 38 out of 69 (55%) of the tumors were diploid (DNA index = 1) while 31 (45%) were aneuploid (DNA index from 1.10 to 2.50 with a median value of 1.50). Ovarian tumors were defined as of low and high S-phase fraction in 68% and 32% of the cases, respectively. Tumor ploidy and S-phase fraction did not correlate with the clinico-pathologic characteristics or p185/neu oncoprotein expression. Aneuploid tumors had a higher S-phase fraction (mean: 15.81 ± 13.44) than diploid tumors (mean: 8.89 ± 7.98) ( P < 0.01). p185/neu expression failed to affect significantly both overall and progression free survival. On the other hand tumor ploidy was found to be related to the prognosis of advanced ovarian cancer patients although the difference was not statistically significant. As far as progression free survival is concerned, the median time to recurrence was not reached for diploid cases whereas it was 21 months for aneuploid cases ( P < 0.05). The 5-year survival for patients with a low S-phase fraction (58%) was significantly higher than for patients with high S-phase fraction tumors (28%) ( P < 0.01). Median time to recurrence was 48 and 17 months for low and high S-phase fraction tumor patients, respectively ( P < 0.05). However, in a multivariate analysis both tumor ploidy and S-phase fraction did not retain their prognostic value. The assessment of the role of the parameters examined in improving the prognostic characterization of ovarian cancer patients should be investigated in large multicenter clinical trials.     

Amplification of HER-2/neu oncogene in human ovarian cancer

Amplification and/or increased expression of the HER-2/neu oncogene has been reported to occur in ovarian tumors and possibly to correlate with biologic behavior and prognosis. The frequency with which amplification is reported to occur is quite variable ranging from 0–30% in different series and this variability is probably accounted for by technical and methodologic factors. The variability and lack of reproducibility has raised questions about the usefulness of assessing amplification of the HER-2/neu oncogene and in particular its clinical relevance. In this study by using strict criteria for amplification and using multiple controls we could demonstrate unequivocal amplification of the HER-2/neu oncogene by Southern blot analysis in only 11% of malignant ovarian tumors. The potential pitfalls with the techniques used to detect HER-2/neu oncogene amplification and overexpression are reviewed and possible ways to overcome some of the problems are suggested.     

HER-2/neu胞外区的基因工程表达及其免疫避孕作用

目的:研究HER-2/neu胞外区部分片段重组蛋白疫苗在免疫避孕中的作用。方法:构建原核表达重组体pET-hECDu,在大肠杆菌中表达人HER-2/neu胞外区部分片段,经Hi-Trap亲和层析柱纯化得到重组蛋白(hECDu),以ELISA法检测其结合活性后免疫雌性小鼠。用ELISA法检测抗HER-2/neu体液免疫应答,3H-TdR掺入法检测细胞免疫应答。结果:经原核表达系统成功纯化得到与理论分子量77 ku(1 u=1 Da)相符的hECDu,并证实其可与抗HER-2/neu胞外区特异性单克隆抗体结合。该重组蛋白疫苗可诱导雌鼠产生较高水平体液及细胞免疫应答。其生育力(平均产仔数4.0±1.8)与对照组(7.8±1.3)相比明显降低,但免疫鼠产后4 d子宫及卵巢均无明显病理改变。结论:经原核表达系统成功纯化得到HER-2/neu胞外区部分片段重组蛋白,该蛋白疫苗可在小鼠中诱导产生免疫避孕效应。